JP2012510438A5 - - Google Patents

Download PDF

Info

Publication number
JP2012510438A5
JP2012510438A5 JP2011537906A JP2011537906A JP2012510438A5 JP 2012510438 A5 JP2012510438 A5 JP 2012510438A5 JP 2011537906 A JP2011537906 A JP 2011537906A JP 2011537906 A JP2011537906 A JP 2011537906A JP 2012510438 A5 JP2012510438 A5 JP 2012510438A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
lipophilic component
surfactant
insulin peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011537906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510438A (ja
Filing date
Publication date
Priority claimed from PCT/EP2009/053017 external-priority patent/WO2009115469A1/en
Application filed filed Critical
Priority claimed from PCT/EP2009/062126 external-priority patent/WO2010060667A1/en
Publication of JP2012510438A publication Critical patent/JP2012510438A/ja
Publication of JP2012510438A5 publication Critical patent/JP2012510438A5/ja
Withdrawn legal-status Critical Current

Links

JP2011537906A 2008-11-28 2009-09-18 誘導体化インスリンペプチドの経口投与に適した医薬組成物 Withdrawn JP2012510438A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08170231.8 2008-11-28
EP08170231 2008-11-28
PCT/EP2009/053017 WO2009115469A1 (en) 2008-03-18 2009-03-13 Protease stabilized, acylated insulin analogues
EPPCT/EP2009/053017 2009-03-13
PCT/EP2009/062126 WO2010060667A1 (en) 2008-11-28 2009-09-18 Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides

Publications (2)

Publication Number Publication Date
JP2012510438A JP2012510438A (ja) 2012-05-10
JP2012510438A5 true JP2012510438A5 (cg-RX-API-DMAC7.html) 2012-09-20

Family

ID=40524842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011537906A Withdrawn JP2012510438A (ja) 2008-11-28 2009-09-18 誘導体化インスリンペプチドの経口投与に適した医薬組成物

Country Status (5)

Country Link
US (1) US20110293714A1 (cg-RX-API-DMAC7.html)
EP (1) EP2370059A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012510438A (cg-RX-API-DMAC7.html)
CN (1) CN102227213A (cg-RX-API-DMAC7.html)
WO (1) WO2010060667A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2514406A1 (en) * 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
AU2008257505B2 (en) * 2007-06-01 2013-05-16 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
BR112012016853A2 (pt) * 2010-01-12 2017-10-17 Novo Nordisk As "composições farmacêuticas para administração oral de peptídeos de insulina".
WO2012006956A1 (zh) 2010-07-14 2012-01-19 中国医学科学院药物研究所 一种胰岛素的脂质复合物及其制备方法和制剂
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー/エス 新規n末端修飾インスリン誘導体
CN103458873B (zh) * 2011-04-14 2016-04-13 诺沃—诺迪斯克有限公司 用于口服肽递送的脂肪酸酰化的氨基酸
WO2013093009A1 (en) 2011-12-21 2013-06-27 Novo Nordisk A/S N -terminally modified insulin derivatives
EA023447B1 (ru) * 2011-12-28 2016-06-30 Борис Славинович ФАРБЕР Производное инсулина, обладающее сахароснижающей активностью при пероральном применении, способ его получения и лекарственные формы на его основе
WO2013128003A1 (en) 2012-03-01 2013-09-06 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
JP6285447B2 (ja) * 2012-10-17 2018-02-28 ノヴォ ノルディスク アー/エス 経口ペプチド送達用の脂肪酸アシル化d−アミノ酸
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
US20160113906A1 (en) * 2014-09-19 2016-04-28 Board Of Regents, The University Of Texas System Methods of preparing extrudates
EP3215128B1 (en) 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
EP3768094B1 (en) 2018-03-15 2024-05-01 R.P. Scherer Technologies, LLC Enteric softgel capsules
MY210034A (en) * 2019-03-15 2025-08-22 Novo Nordisk As Process for spray drying a glp-1 peptide
JP7778509B2 (ja) * 2021-09-24 2025-12-02 株式会社 資生堂 化粧料

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US20070292523A1 (en) * 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
EP2514406A1 (en) * 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
WO2009022006A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids

Similar Documents

Publication Publication Date Title
RU2012133075A (ru) Фармацевтическая композиция для перорального введения инсулиновых пептидов
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
AR045490A1 (es) Glucopiranosiloxi - pirazoles, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparacion
WO2013043841A8 (en) Cleaning formulations with improved surfactant solubility and methods of production and use thereof
JP6320442B2 (ja) エレクトロウェッティング素子及び流体
UA102477C2 (en) Capsule composition
NZ590496A (en) Hard surface cleaning composition
AR045906A1 (es) Composicion farmaceutica para mejorar la solubilidad de farmacos hidrofobicos
AR073880A1 (es) Un compuesto heterociclico, composicion farmaceutica que lo compone y metodos para inhibir la proteasa ns3/ns4 y para incrementar la funcion hepatica con dichos compuesto y metodo para tratar fibrosis hepatica con los mismos.
AR071533A1 (es) Microemulsion mejorada con un amplio rango de aplicacion
GB0218002D0 (en) Pharmaceutical compositions
RU2016114537A (ru) Композиции антагонистов рецепторов cgrp
NZ603699A (en) Injectable parasiticidal formulations of levamisole and macrocyclic lactones
WO2008099835A1 (ja) Peg充填硬質カプセル剤のバンドシール
AR054778A1 (es) Uso de sangliferina en hcv
CA2600023A1 (en) Solvent system for enhancing the solubility of pharmaceutical agents
JP2013528838A5 (cg-RX-API-DMAC7.html)
ES2786749T3 (es) Composición farmacéutica para administración oral que comprende una concentración elevada de taxano
BR112014003103B1 (pt) composição de limpeza, método para remover uma sujidade graxa e método para fazer um limpador de superfície desengraxante
RU2011101688A (ru) Сосуд для медицинских препаратов и способ его изготовления
JP2009242356A (ja) 洗浄料
RU2006100112A (ru) Трансназальные микроэмульсии, содержащие диазепам
KR101612259B1 (ko) 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
NL2028762B1 (en) Micelle-generating formulations for enhanced bioavailability
EP3326652B1 (en) Pharmaceutical composition for oral administration comprising high concentration taxane